MYM Nutraceuticals Inc. (CSE:MYM) (FRANKFURT:0MY) (OTCMKTS:MYMMF) (“MYM” or the “Company” is pleased to announce that it has established an at-the-market equity distribution program (“ATM Program”) that allows the Company to issue common shares from treasury (“Common Shares”), through GMP Securities L.P., as agent (the “Agent”), to the public from time to time at the Company’s discretion, at the prevailing market price when sold through the Canadian Securities Exchange (“CSE”) or on any other existing trading market for the Common Shares in Canada.

Sales of Common Shares under the ATM Program will be made pursuant to the terms of an equity distribution agreement dated October 17, 2018 (“Equity Distribution Agreement”) between the Company and the Agent.


Sales of Common Shares will be made through “at-the-market distributions”, as defined in National Instrument 44-102 – Shelf Distributions, on the CSE or on any other existing trading market for the Common Shares in Canada. The Common Shares will be distributed at the prevailing market prices at the time of the sale and, as a result, prices may vary among purchasers and during the period of distribution.

Sale of Common Shares under the ATM Program are being made pursuant to a prospectus supplement dated October 17, 2018 (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated October 9, 2018 (the “Base Shelf Prospectus”). Copies of the Prospectus Supplement, the Base Shelf Prospectus and the Equity Distribution Agreement may be obtained on request without charge from the Corporate Secretary of MYM Nutraceuticals Inc. at Suite 250, 1095 West Pender Street, Vancouver, British Columbia, V6E 2M6, Telephone (604) 899-5267, and are also available electronically on SEDAR at www.sedar.com.

The Company intends to use the net proceeds from the ATM Program, if any, to fund ongoing operations, capital expenditures and potential future acquisitions or investments. For further information on the use of net proceeds from the ATM Program, see the “Use of Proceeds” section in the Prospectus Supplement.

This news release shall not in any circumstances constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to the registration or qualification under the applicable securities laws of any jurisdiction.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a shareholder in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

On behalf of the Board of Directors

“Erick Factor”

Executive Chairman

Investor Relations

investors@mym.ca mailto:

FORWARD-LOOKING STATEMENTS

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE), nor its Regulatory Services provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

Certain statements (“forward-looking statements”) in this news release may contain forward-looking information concerning the anticipated sale and distribution of Common Shares under the ATM Program, the volume and timing of the sale and distribution of Common Shares under the ATM Program, the Company’s intended use of the net proceeds from the ATM Program, plans related to the Company’s business, the anticipated production capacity of the Company’s projects and other matters that may occur in the future, made as of the date of this news release. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Such factors include, among others, risks related to MYM’s ability to raise capital under the ATM Program or additional capital, the Company’s use of proceeds, the Company’s ability to fulfill its obligations under the Equity Distribution Agreement and the Company’s ability to complete its production projects as anticipated. Forward-looking statements are based on certain assumptions that management believes are reasonable at the time they are made. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including, but not limited to, that the Company will be able to raise capital under the ATM Program or any additional capital and the use of the proceeds will proceed as planned, the Company and other parties will be able to complete and satisfy obligations under the Equity Distribution Agreement and the Company will be able to complete its production projects as anticipated. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation.

Source: www.thenewswire.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less